Atalanta Therapeutics
PrivateLast Round
Series B
Jan 28, 2025
Total Funding Raised
$207M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Atalanta Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in January 2025.
Atalanta Therapeutics is a biotechnology company that develops RNA interference therapeutics aimed at treating neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atalanta Therapeutics Comparables
Compare Atalanta Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| City Therapeutics | 84% | |
| Switch Therapeutics | 83% | |
| Trace Neuroscience | 83% |
For institutional investors. Book with your work email.
Atalanta Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 28, 2025 | ||||
| Series A | Jan 11, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Atalanta Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series B |
| EQT Ventures | Series B |
| Mirae Asset | Series B |
| abrdn Inc. | Series B |
| F-Prime Capital | Series B, Series A |
| Genentech | Series A |
| GHR Foundation | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 37% MoM, reaching 3.6K.
- Jun 18, 2025
Alicia Secor stepped down as Chief Executive Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 14, 2026
Atalanta is currently developing a standalone MSH3-targeting di-siRNA and dual-targeting approaches for HTT and MSH3 as complementary therapeutic approaches to address disease progression.
For institutional investors. Book with your work email.
Atalanta Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Atalanta Therapeutics's valuation, stock price, and market status.
Is Atalanta Therapeutics a public or private company?
Atalanta Therapeutics is a private company.
What is the current stock price of Atalanta Therapeutics?
Atalanta Therapeutics is a private company, so its shares have no public market price. Caplight tracks Atalanta Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Atalanta Therapeutics worth (valuation)?
Valuation information for Atalanta Therapeutics is not publicly available.
Can I buy Atalanta Therapeutics stock?
Atalanta Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Atalanta Therapeutics's last funding round?
Atalanta Therapeutics's most recent funding round was Series B on January 28, 2025.
Who are the main investors in Atalanta Therapeutics?
Key investors in Atalanta Therapeutics include EQT Life Sciences, EQT Ventures, F-Prime Capital, F-Prime Capital, Sanofi Ventures.
Will Atalanta Therapeutics IPO soon?
No public IPO plans have been announced for Atalanta Therapeutics.
How can I track Atalanta Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Atalanta Therapeutics's shares on secondary markets.